509226 Sigma-AldrichPI 3-K Inhibitor XXI, GDC-0941 - CAS 957054-30-7 - Calbiochem
A cell-permeable, potent, ATP-competitive inhibitor of class IA (IC₅₀ = 3 nM/p110α, 33 nM/p110&beta, 3 nM/p110δ) and IB PI 3-kinases (IC₅₀ = 75 nM/p110γ).
More>> A cell-permeable, potent, ATP-competitive inhibitor of class IA (IC₅₀ = 3 nM/p110α, 33 nM/p110&beta, 3 nM/p110δ) and IB PI 3-kinases (IC₅₀ = 75 nM/p110γ). Less<<Synonymes: GDC0941, 2-(1H-Indazol-4-yl)-6-(4-methylsulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d]pyrimidine, 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine
Produits recommandés
Aperçu
Replacement Information |
---|
Tableau de caractéristiques principal
CAS # | Empirical Formula |
---|---|
957054-30-7 | C₂₃H₂₇N₇O₃S₂ |
Products
Référence | Conditionnement | Qté | |
---|---|---|---|
5092260001 | Flacon en verre | 10 mg |
Product Information | |
---|---|
CAS number | 957054-30-7 |
Form | White solid |
Hill Formula | C₂₃H₂₇N₇O₃S₂ |
Chemical formula | C₂₃H₂₇N₇O₃S₂ |
Reversible | Y |
Structure formula Image | |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | PI 3-K |
Purity | ≥99% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Référence | GTIN |
5092260001 | 04055977241693 |
Documentation
PI 3-K Inhibitor XXI, GDC-0941 - CAS 957054-30-7 - Calbiochem FDS
Titre |
---|
Références bibliographiques
Aperçu de la référence bibliographique |
---|
Tabe, Y., et al. 2014. Acta Haematol. 131, 59. Ware, J.A., et al. 2013. Mol. Pharm. 10, 4047. Junttila,.T., et al. 2009. Cancer Cell 15, 429. Raynaud, F.I., et al. 2009. Mol Cancer Ther. 8, 1725. Folkes, A. J., et al. 2008. J. Med. Chem. 51, 5522. |